These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 18559673)

  • 1. Clinical and in vitro resistance to bexarotene in adult T-cell leukemia: loss of RXR-alpha receptor.
    Lin JH; Kim EJ; Bansal A; Seykora J; Richardson SK; Cha XY; Zafar S; Nasta S; Wysocka M; Benoit B; Rook AH; Fakharzadeh SS
    Blood; 2008 Sep; 112(6):2484-8. PubMed ID: 18559673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Isochroman Analog of CD3254 and Allyl-, Isochroman-Analogs of NEt-TMN Prove to Be More Potent Retinoid-X-Receptor (RXR) Selective Agonists Than Bexarotene.
    Jurutka PW; di Martino O; Reshi S; Mallick S; Sausedo MA; Moen GA; Lee IJ; Ivan DJ; Krall TD; Peoples SJ; Perez A; Tromba L; Le A; Khadka I; Petros R; Savage BM; Salama E; Salama J; Ziller JW; Noh Y; Lee MY; Liu W; Welch JS; Marshall PA; Wagner CE
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of Bexarotene Analogs for Treating Cutaneous T-Cell Lymphomas.
    Warda A; Staniszewski LJP; Sabir Z; Livingston S; Sausedo M; Reshi S; Ron E; Applegate MT; Haddad D; Khamisi M; Marshall PA; Wagner CE; Jurutka PW
    Cells; 2023 Nov; 12(21):. PubMed ID: 37947652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absence of modulation of CD4+CD25 regulatory T cells in CTCL patients treated with bexarotene.
    Knol AC; Quéreux G; Brocard A; Ballanger F; Khammari A; Nguyen JM; Dréno B
    Exp Dermatol; 2010 Aug; 19(8):e95-102. PubMed ID: 19845755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing bexarotene therapy for cutaneous T-cell lymphoma.
    Talpur R; Ward S; Apisarnthanarax N; Breuer-Mcham J; Duvic M
    J Am Acad Dermatol; 2002 Nov; 47(5):672-84. PubMed ID: 12399758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling, Synthesis, and Biological Evaluation of Potential Retinoid-X-Receptor (RXR) Selective Agonists: Analogs of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahyro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene) and 6-(Ethyl(4-isobutoxy-3-isopropylphenyl)amino)nicotinic Acid (NEt-4IB).
    Jurutka PW; di Martino O; Reshi S; Mallick S; Sabir ZL; Staniszewski LJP; Warda A; Maiorella EL; Minasian A; Davidson J; Ibrahim SJ; Raban S; Haddad D; Khamisi M; Suban SL; Dawson BJ; Candia R; Ziller JW; Lee MY; Liu C; Liu W; Marshall PA; Welch JS; Wagner CE
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action.
    Zhang C; Hazarika P; Ni X; Weidner DA; Duvic M
    Clin Cancer Res; 2002 May; 8(5):1234-40. PubMed ID: 12006543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox.
    Gorgun G; Foss F
    Blood; 2002 Aug; 100(4):1399-403. PubMed ID: 12149223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results.
    Duvic M; Hymes K; Heald P; Breneman D; Martin AG; Myskowski P; Crowley C; Yocum RC;
    J Clin Oncol; 2001 May; 19(9):2456-71. PubMed ID: 11331325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemopreventive effects of RXR-selective rexinoid bexarotene on intestinal neoplasia of Apc(Min/+) mice.
    Janakiram NB; Mohammed A; Qian L; Choi CI; Steele VE; Rao CV
    Neoplasia; 2012 Feb; 14(2):159-68. PubMed ID: 22431924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A naturally occurring rexinoid, honokiol, can serve as a regulator of various retinoid x receptor heterodimers.
    Kotani H; Tanabe H; Mizukami H; Amagaya S; Inoue M
    Biol Pharm Bull; 2012; 35(1):1-9. PubMed ID: 22223330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma.
    Nieto-Rementería N; Pérez-Yarza G; Boyano MD; Apraiz A; Izu R; Díaz-Pérez JL; Asumendi A
    Br J Dermatol; 2009 Mar; 160(3):519-26. PubMed ID: 19067706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rexinoid bexarotene modulates triglyceride but not cholesterol metabolism via gene-specific permissivity of the RXR/LXR heterodimer in the liver.
    Lalloyer F; Pedersen TA; Gross B; Lestavel S; Yous S; Vallez E; Gustafsson JA; Mandrup S; Fiévet C; Staels B; Tailleux A
    Arterioscler Thromb Vasc Biol; 2009 Oct; 29(10):1488-95. PubMed ID: 19592467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic treatment of psoriatic patients with bexarotene decreases epidermal proliferation and parameters for inflammation, and improves differentiation in lesional skin.
    Smit JV; de Jong EM; van Hooijdonk CA; Otero ME; Boezeman JB; van de Kerkhof PC
    J Am Acad Dermatol; 2004 Aug; 51(2):257-64. PubMed ID: 15280845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling, synthesis and biological evaluation of potential retinoid X receptor-selective agonists: novel halogenated analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene).
    Furmick JK; Kaneko I; Walsh AN; Yang J; Bhogal JS; Gray GM; Baso JC; Browder DO; Prentice JL; Montano LA; Huynh CC; Marcus LM; Tsosie DG; Kwon JS; Quezada A; Reyes NM; Lemming B; Saini P; van der Vaart A; Groy TL; Marshall PA; Jurutka PW; Wagner CE
    ChemMedChem; 2012 Sep; 7(9):1551-66. PubMed ID: 22927238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma.
    Foss F; Demierre MF; DiVenuti G
    Blood; 2005 Jul; 106(2):454-7. PubMed ID: 15811959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bexarotene.
    Lowe MN; Plosker GL
    Am J Clin Dermatol; 2000; 1(4):245-50; discussion 251-2. PubMed ID: 11702369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling, synthesis and biological evaluation of potential retinoid X receptor (RXR) selective agonists: novel analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene).
    Wagner CE; Jurutka PW; Marshall PA; Groy TL; van der Vaart A; Ziller JW; Furmick JK; Graeber ME; Matro E; Miguel BV; Tran IT; Kwon J; Tedeschi JN; Moosavi S; Danishyar A; Philp JS; Khamees RO; Jackson JN; Grupe DK; Badshah SL; Hart JW
    J Med Chem; 2009 Oct; 52(19):5950-66. PubMed ID: 19791803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methods to Assess Activity and Potency of Rexinoids Using Rapid Luciferase-Based Assays: A Case Study with NEt-TMN.
    Jurutka PW; Wagner CE
    Methods Mol Biol; 2019; 2019():95-108. PubMed ID: 31359391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of oral bexarotene (targretin) on the minimal erythema dose for broadspectrum UVB light.
    Smit JV; De Jong EM; Van De Kerkhof PC
    Skin Pharmacol Appl Skin Physiol; 2003; 16(4):237-41. PubMed ID: 12784063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.